Silver Set to Shine: The (Very) Long Term View

Source: Seeking Alpha (6/4/07)

In 48 years silver gained 200 fold over its competing assets. In the next 48 years between 1993 and some time around 2040 we may see silver grow 200 fold again to spike at $700 an ounce ($3.50 multiplied by 200).

Back in the depression year of 1932 silver was suffering. It had hit a low price of 24 cents per troy ounce...As it turned out, this was the nadir year for silver as prices began an upturn that led to a zenith as yet unparalleled. Between 1932 and 1980 silver advanced from 24 cents to 50 dollars an ounce. That is a 200-fold increase over 48 years!...

Perhaps readers can enlighten me to other asset classes which may have beaten the performance silver put in between 1932 and 1980 but for now silver takes the award as the best performing asset in that cycle between one deflation low and one inflation high.

So why am I saying this now? Silver hit another major low back in 1993 when it reached $3.50. These two numbers are interesting. If we go to the standard CPI inflation calculator here and type in the years 1932 and 1993 for one dollar, you get the answer that one dollar in 1932 had $10.55 purchasing power in 1993. Multiply our rock bottom silver price of 24 cents by 10.55 and you get a 1993 price of $2.56, which is not too far off our major low in 1993 and makes one wonder whether we had witnessed two similar events but in different cycles.

...In 48 years silver gained 200 fold over its competing assets. In the next 48 years between 1993 and some time around 2040 we may see silver grow 200 fold again to spike at $700 an ounce ($3.50 multiplied by 200).

Align Technology Shares Grind 12.5% Higher after Firm Posts Record Q4 Revenue of $834.5 Million
Source: Streetwise Reports (02/04/2021)

Align Technology shares set a new 52-week high after the company announced financial results that included record FY/20 total revenues of $2.5 billion.

Small-Cap Psychedelic Wellness Company Makes First Acquisition: Ketamine Infusion Centers
Source: Streetwise Reports (02/04/2021)

DELIC aims to become a leader in psychedelic health and wellness clinics.

GW Pharmaceuticals Shares Gain 46% on $7.2 Billion Acquisition by Jazz Pharmaceuticals
Source: Streetwise Reports (02/03/2021)

Shares of GW Pharmaceuticals reached a new 52-week high after the company reported it agreed to be acquired by Jazz Pharmaceuticals in a combination cash and stock deal for $220.00 per share.

Shares of Cassava Sciences traded 207% higher after the firm provided an interim analysis from an ongoing study demonstrating that simufilam improves cognition and behavior in mild-to-moderate Alzheimer's disease patients.

Viela Bio Shares Rise 52% on $3.05 Billion Buyout by Horizon Therapeutics
Source: Streetwise Reports (02/01/2021)

Shares of Viela Bio traded higher after it was announced that the company entered into a definitive agreement to be acquired by Horizon Therapeutics for $53.00 per share.

Algernon Pharmaceuticals, a clinical stage pharmaceutical development company, announced that it has established a clinical research program for the treatment of stroke focused on AP-188 (DMT), a known psychedelic compound. Algernon plans to be the first company globally to pursue DMT for stroke in humans and is planning to begin a clinical trial as soon as possible in 2021.

Novavax Shares Shoot 65% Higher on Phase 3 COVID-19 Vaccine Trial's 89.3% Effectiveness
Source: Streetwise Reports (01/29/2021)

Novavax Inc. shares established a new 52-week high after the firm's COVID-19 vaccine demonstrated an 89.3% efficacy rate in a Phase 3 trial in the U.K. and also showed efficacy against the South African variant in a Phase 2b trial.

Abiomed Shares Gain 8% After Firm Announces Record Q3 Revenue of $232 Million
Source: Streetwise Reports (01/28/2021)

Shares of cardiac medical device maker Abiomed Inc. traded higher after the company reported record revenue for Q3/21 despite the impact from COVID-19.

Sorrento Shares Rise 35% After Firm Posts Positive Data from Phase 1b ICU COVID-19 Trial
Source: Streetwise Reports (01/27/2021)

Shares of Sorrento Therapeutics traded higher after the company released positive preliminary results from it of Phase 1b COVI-MSC™ Study for treatment of hospitalized ICU COVID-19 patients.

Junior Mining Sector 'the Best Value in the Space'
Source: Streetwise Reports (01/27/2021)

The StreetSmart Live! Broadcast on Jan. 26, 2021, focused on metals and why now is a good time for investors to be looking at them and the mining space. John Newell, independent analyst and portfolio manager, and John Feneck, mining sector expert and president of Feneck Consulting, addressed the status of the current metals market. CEOs of the three metals-focused companies comprising the Metallic Group of Companies—Group Ten Metals, Metallic Minerals and Granite Creek Copper—discussed their projects.